UroToday

Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.

To evaluate demographic and clinical factors associated with non-compliance with intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle invasive bladder cancer (NMIBC). A ...
UroToday

Preclinical Study Evaluates p300 Protein in AR-Driven Prostate Cancer - Jie Luo

Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...
UroToday

LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
UroToday

Antibiotic-Augmented Irrigation During Ureteroscopy in High-Risk Patients "Presentation" - Kriselle Madamba

At the World Congress of Endourology and Uro-Technology, Kriselle Madamba presented research on antibiotic-augmented irrigation using neomycin and polymyxin B during ureteroscopy to reduce ...
UroToday

Comparing Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia - Dean Elterman

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

DARPin-Based Radioligand Therapy Targets DLL3 with Lead-212 for Cancer Treatment - Philippe Legenne

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

FAP and Nectin-4 Targeted Imaging and Therapy in Urothelial Cancer "Presentation" - Vadim Koshkin

At the 2025 UCSF-UCLA PSMA Conference, Vadim Koshkin discusses radioligand therapies for bladder cancer. He highlights that gallium-FAP-2286 imaging shows bladder cancer has the highest FAP uptake ...
UroToday

TROP2 as Alternative Target for Metastatic Prostate Cancer Imaging and Therapy "Presentation" - Tanya Stoyanova

At the 2025 UCSF-UCLA PSMA Conference, Tanya Stoyanova discusses TROP2 as a promising alternative target for prostate cancer imaging and radiotherapy. She highlights that 25% of metastatic ...
UroToday

The Details Are in the Core: Advancing Prostate Tissue Collection - James Wysock

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...
UroToday

Can We Kill the Bone Scan? "Presentation" - Daniel Spratt

At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...
UroToday

Incorporating PSMA PET into Clinical Trials "Presentation" - Michael Morris

At the 2025 UCSF-UCLA PSMA Conference, Michael Morris discusses radioligand therapy strategies for polymetastatic castration-sensitive prostate cancer. He highlights longer survival timelines ...
UroToday

Improving PSA Doubling Time Calculation for High Risk Biochemical Recurrence - Alicia Morgans

Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a ...